AZ 960 (AZ-960) is a novel, potent, selective and ATP competitive JAK2 (janus kinase) inhibitor with potential antitumor activity. It inhibits JAK2 with an IC50 and Ki of<3 nM and 0.45 nM, and displays 3-fold selectivity for JAK2 over JAK3. It shows potent in vitro antiproliferative activity and high in vivo antitumor efficacy. In recent studies, AZ960 demonstrates potential anti-cancer activity against adult T-cell leukemia (ATL), an aggressive malignancy of CD4+ T lymphocytes, by effectively inducing growth arrest and apoptosis in human T-cell lumphotropic virus type 1 (HTLV-1) infected T cells.
Physicochemical Properties
| Molecular Formula | C18H16F2N6 | |
| Molecular Weight | 354.36 | |
| Exact Mass | 354.14 | |
| Elemental Analysis | C, 61.01; H, 4.55; F, 10.72; N, 23.72 | |
| CAS # | 905586-69-8 | |
| Related CAS # |
|
|
| PubChem CID | 25099184 | |
| Appearance | Solid powder | |
| Density | 1.4±0.1 g/cm3 | |
| Boiling Point | 515.2±50.0 °C at 760 mmHg | |
| Flash Point | 265.4±30.1 °C | |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C | |
| Index of Refraction | 1.628 | |
| LogP | 6.09 | |
| Hydrogen Bond Donor Count | 3 | |
| Hydrogen Bond Acceptor Count | 7 | |
| Rotatable Bond Count | 5 | |
| Heavy Atom Count | 26 | |
| Complexity | 503 | |
| Defined Atom Stereocenter Count | 1 | |
| SMILES | N(C1N=C(NC2=NNC(C)=C2)C(F)=CC=1C#N)[C@H](C1C=CC(F)=CC=1)C |
|
| InChi Key | SUNXHXDJOIXABJ-NSHDSACASA-N | |
| InChi Code | InChI=1S/C18H16F2N6/c1-10-7-16(26-25-10)23-18-15(20)8-13(9-21)17(24-18)22-11(2)12-3-5-14(19)6-4-12/h3-8,11H,1-2H3,(H3,22,23,24,25,26)/t11-/m0/s1 | |
| Chemical Name | 5-fluoro-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Jak2 kinase is inhibited by AZ960 at a Ki of 0.45 nM. Z960 has significantly less activity against TYK2, Jak1, and 3. AZ960 has an IC50 of about 0.1 μM and is active against various kinases, including as FAK, TrkA, and Aurora-A. In human T-cell lymphotropic virus type 1, HTLV-1-infected T cells (MT-1 and MT-2), AZ960 efficiently induces growth arrest and death while downregulating the phosphorylated versions of Jak2 and Bcl-2 family proteins, including Bcl-2 and Mcl-1[2]. In recently isolated acute myeloid leukemia cells, AZ960 efficiently suppresses clonal proliferation and triggers apoptosis, which is linked to caspase 3 cleavage and downregulation of the anti-apoptotic Bcl-xL protein [1]. The AZ960 Ki for T. The value of TbERK8, or Brucei extracellular signal-regulated kinase 8, is 1.25 μM. With an IC50 of 120 nM, it inhibits TbERK8[3]. | ||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
[1]. Ikezoe T, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer. 2011 Nov 15;129(10):2512-21. [2]. Gozgit JM, et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43. [3]. Yang J, et al. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells. Mol Cancer Ther. 2010 Dec;9(12):3386-95. [4]. Valenciano AL, et al. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor. Bioorg Med Chem. 2016 Oct 1;24(19):4647-51 |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8220 mL | 14.1099 mL | 28.2199 mL | |
| 5 mM | 0.5644 mL | 2.8220 mL | 5.6440 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8220 mL |